ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 10 Issue 2, Summer/Fall 1996 Special Commemorative Issue

August 13, 1996

Wilmot Researchers Study Combination for Lymphoma

September 26, 2003

Crout Resigns As Director Of FDA Drugs Bureau

July 11, 1980

DeVita Dissatisfied With Cooperative Groups on Accrual; NCAB to Hear Wittes’ Plan In Feb.

November 20, 1987

Amgen’s Kepivance Approved For Severe Oral Mucositis

January 28, 2005

Limit On Number Of Surgery Planning Grants Lifted After DCT Board Pressure

March 19, 1982